PRESS RELEASE published on 10/10/2025 at 18:17, 8 months 8 days ago Rapport financier semestriel 2025
BRIEF published on 08/04/2025 at 08:03, 10 months 15 days ago AB Science finalise un placement privé de 2,55 millions d'euros Actionnaires Placement Privé Développement Clinique AB Science 2,55 Millions D'euros
BRIEF published on 08/04/2025 at 08:03, 10 months 15 days ago AB Science Completes EUR 2.55 Million Private Placement Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE published on 08/04/2025 at 07:58, 10 months 15 days ago AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’euros AB Science annonce le succès d'un placement privé de 2,55 millions d'euros pour financer le développement clinique du programme AB8939 Capital Financement Placement Privé AB Science Programme AB8939
PRESS RELEASE published on 08/04/2025 at 07:58, 10 months 15 days ago AB Science announces the successful completion of a 2.55 million euros private placement AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF published on 07/30/2025 at 07:50, 10 months 20 days ago AB Science Advances in AML Study With New European Approvals Regulatory Approval Market Potential AB8939 Venetoclax AML Study
BRIEF published on 07/30/2025 at 07:50, 10 months 20 days ago AB Science progresse dans l'étude sur la LAM grâce à de nouvelles autorisations européennes Approbation Réglementaire Potentiel Du Marché AB8939 Venetoclax Étude Sur La LAM
PRESS RELEASE published on 07/30/2025 at 07:45, 10 months 20 days ago AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA AB Science reçoit l'approbation réglementaire pour la phase I/II de l'étude combinant AB8939 et venetoclax dans le traitement de la leucémie myéloïde aiguë. Étude en cours en Europe AB Science AB8939 Leucémie Myéloïde Aiguë Venetoclax Phase I/II
PRESS RELEASE published on 07/30/2025 at 07:45, 10 months 20 days ago AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF published on 07/24/2025 at 08:01, 10 months 26 days ago AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe Phase 3 Trial ALS AB Science Masitinib European Approval
Published on 06/19/2026 at 04:30, 7 hours 16 minutes ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 10 hours 26 minutes ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 10 hours 39 minutes ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:00, 11 hours 46 minutes ago Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/19/2026 at 11:30, 15 minutes ago Ottobock sells its Human Mobility wheelchair business
Published on 06/19/2026 at 11:05, 40 minutes ago INTCO Medical Showcases Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy Solutions at WHX Miami 2026
Published on 06/19/2026 at 10:52, 53 minutes ago HELIOS SOLAR AG Adjusts Start of Subscription Period to June 29, 2026
Published on 06/19/2026 at 09:48, 1 hour 57 minutes ago Edison issues report on Social Housing REIT (SOHO)
Published on 06/19/2026 at 08:55, 2 hours 51 minutes ago ALPOU - Groupe POULAILLON - Communiqué mise à disposition de la note d'information et DAI relatif à la société visée
Published on 06/19/2026 at 08:55, 2 hours 51 minutes ago ALPOU - Groupe POULAILLON - Communiqué mise à disposition de la note d'information et DAI relatif à EUGENIE
Published on 06/19/2026 at 08:49, 2 hours 56 minutes ago Groupe DLSI - Evolution de la gouvernance et recomposition du Directoire
Published on 06/18/2026 at 18:00, 17 hours 46 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 mai 2026
Published on 06/18/2026 at 18:00, 17 hours 46 minutes ago Outstanding shares and voting rights statement at 31 May 2026